Search for companies, drugs, and catalysts
Phase 2
Development Phase
1
Upcoming Catalysts
0
Historical Events
Regulatory Approvals
SAR441344 IV Phase 2 Results Expected
SAR441344 IV • Systemic Lupus Erythematosus
Target Indication
Systemic Lupus Erythematosus
Clinical Trial
Last updated: 12/8/2025
SNY
Sanofi
Alzheimer Disease
Sleep Initiation and Maintenance Disorders
Hemophilia A
Ulcerative Colitis
Influenza